US Drug Pricing Reform: Potential impact on Pharma HEOR evidence generation

Prior to joining Cytel, Anna Forsythe cofounded PSE with the vision of providing curated evidence and economic modeling to support global HTA. Anna maintains close partnerships to ensure continuous alignment with the client’s strategic objectives. She capitalizes on her insights developed over more than two decades in global product commercialization, strategic drug development, market access, HEOR, and pricing and reimbursement. Anna’s most recent role was Executive Director and Head of Global Value and Access Strategy at Eisai. A thought leader in HEOR, Anna is an adjunct health economics professor at Long Island University College of Pharmacy, a guest lecturer at Rutgers University Business School, and a frequent contributor to forums, articles, and conferences addressing healthcare value and access. In addition to her PharmD and MBA, Anna earned a MS in Health Economics and Public Policy from the University of Birmingham.

Dr. Pezalla is a leading payer expert consulting for pharmaceutical and device developers and manufacturers on public policy, health technology assessment, and value frameworks. He is active on a number of policy working groups including the New Drug Development Paradigm Project at MIT. He has recently been named a Scholar-in-Residence at the Duke-Margolis Health Policy Center in Washington, DC where he is working on policy approaches to stimulating the development of new antimicrobials, evaluation of value frameworks, and other policy projects. Dr. Pezalla is a member of the Board of Directors of the Pharmacy Quality Alliance and the Connecticut Biosciences Innovation Fund. He is also a member of the Business Advisory Board of Naia Pharmaceuticals and the Scientific Advisory Board of Temple Therapeutics.